Low prevalence of active cytomegalovirus infection in a cardiovascular intensive care unit

Journal of Intensive Care

Volumn 2, Issue 1, 2014, Pages

  Ishioka, Haruhiko ^a   Sanui, Masamitsu ^a   Tsutsumi, Yusuke ^a,b   Yanase, Fumitaka ^a   Shiotsuka, Junji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antigen; Cardiovascular surgery; Cytomegalovirus; Epidemiology; Incidence; Intensive care unit

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; IMMUNOGLOBULIN G;

AGED; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SURGERY; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; FEMALE; GENDER; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LETTER; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; OPERATION DURATION; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY;

EID: 84979198280     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/2052-0492-2-12     Document Type: Letter

References (9)

1. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 2009, 37:2350-2358. 10.1097/CCM.0b013e3181a3aa43, 19531944.
2. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, Dzavik V, McQueen M, Yusuf S, . Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003, 107:251-257. 10.1161/01.CIR.0000044940.65226.1F, 12538424, Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
3. Crumpacker CS, Zhang JL. Cytomegalovirus. Principles and Practice of Infectious Diseases 2010, 1971-1987. Philadelphia: Elsevier Churchill Livingstone, Mandell GL, Bennett JE, Dolin R, 7.
4. Prösch S, Wendt CE, Reinke P, Priemer C, Oppert M, Krüger DH, Volk HD, Döcke WD. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology 2000, 272:357-365. 10.1006/viro.2000.0367, 10873779.
5. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M. Cytomegalovirus reactivation in critically Ill immunocompetent patients. JAMA 2008, 300:413-422. 2774501, 18647984.
6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
7. Kuo CP, Wu CL, Ho HT, Chen CG, Liu SI, Lu YT. Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy. Clin Microbiol Infect 2008, 14:221-227. 10.1111/j.1469-0691.2007.01895.x, 18070129.
8. Cook CH, Trgovcich J. Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges. Antiviral Res 2011, 90:151-159. 10.1016/j.antiviral.2011.03.179, 3129598, 21439328.
9. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86:3598-3603.